#USA #Cambridge #Marengo Therapeutics #Invikafusp Alfa #STARt-001

Marengo Therapeutics Completes Enrollment for STARt-001

Marengo Therapeutics, Inc., a biotechnology firm focused on precision immunotherapies for cancer and autoimmune disorders, recently announced that it has completed enrollment in the Phase 1/2 STARt-001 clinical trial for invikafusp alfa. This trial specifically targets patients with PD-1–resistant and antigen-rich solid tumors. The company has also indicated that important results from this study will be presented orally at the upcoming ESMO 2026 Congress in Madrid, Spain, scheduled for October 23-27.

Advancements in Clinical Development

Invikafusp alfa is emerging as a crucial candidate in the fight against various tumor types that have shown resistance to traditional PD-1-directed therapies. As top executives from Marengo underscore the significance of this trial, Zhen Su, M.D., and CEO of Marengo, described the recently completed enrollment as a significant milestone that underscores the drug's potential to serve as a pan-tumor immuno-oncology backbone. This potential is especially compelling for patients dealing with tumors that do not respond to existing treatments.

The ongoing efforts in the STARt-001 clinical trial include not just monotherapy cohorts, but also standard care combination cohorts, which will expand the scope of understanding the drug's efficacy across multiple treatment scenarios. Furthermore, updated results from the study point towards its effectiveness across eight distinct PD-1–resistant tumors, such as MSS colorectal cancer and triple-negative breast cancer.

Leadership in Focus

Parallel to the exciting trial developments, Marengo has strengthened its leadership team with the appointments of Amy Otto as Senior Vice President for Program Leadership and Dr. Zhenming Shun as Senior Vice President for Data Science. With more than 20 years of experience in oncology development at major biopharmaceutical companies, Amy Otto is expected to play a pivotal role in guiding the integrated strategies for invikafusp alfa. Her background includes significant roles at companies like Amgen and Gilead, where she was instrumental in shaping oncology strategies and guiding projects from early development to market launch.

Dr. Shun, known for his three decades of experience, will oversee biostatistics and data management, supporting the drug's statistical strategy. His expertise is particularly valuable as Marengo seeks to leverage the emerging dataset from invikafusp alfa to enhance its clinical development plans.

Looking Ahead

The upcoming ESMO presentation is poised to set the stage for discussing invikafusp alfa's future with the U.S. Food and Drug Administration (FDA). The company aims to align its development plan to ensure that the next stage of the clinical journey begins in 2027, making continuous progress a priority.

As Marengo Therapeutics seeks to refine its trials and enhance its strategic leadership, the focus remains on demonstrating invikafusp alfa's efficacy among diverse patient populations, especially those currently lacking effective treatment options. This rigorous approach positions the company at the forefront of biotechnology innovation, particularly in the realm of cancer therapies.

In conclusion, with a promising candidate like invikafusp alfa progressing toward late-stage clinical development and bolstered by expert leadership, Marengo Therapeutics is setting itself on a path to potentially transform cancer treatment landscapes, providing hope for patients resistant to existing therapies. For further insights, stakeholders are encouraged to check the company’s detailed updates and presentations at industry conferences, particularly the much-anticipated ESMO Congress.